Tag Archives: Breast

Gap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by Enough

By Amy Norton HealthDay Reporter FRIDAY, July 2, 2021 — Racial disparities in breast cancer survival have narrowed in recent years, but Black women with the disease still have double the death rate of white women. That’s according to a study that tracked breast cancer trends in Florida between 1990 and 2015. Overall, deaths from… Read More »

What Vitamin is Good for Breast Health?

Learn what vitamin is good for breast health. Supporting healthy breast tissue is no longer a taboo topic. Many breast cancer awareness programs have been successful in teaching women the importance of regular health screenings and at-home self-checks. In addition to screenings, there are many ways to support breast health, including lifestyle changes like diet… Read More »

Pfizer’s Ibrance kisses early breast cancer hopes goodbye with second study failure

After Pfizer’s Ibrance failed a crucial study in HR-positive, HR-negative postsurgery breast cancer patients, the company clung to hope that it could still show a benefit in a high-risk subset of those patients. But new data have officially snuffed out those hopes. There’s “no saving adjuvant for Ibrance,” SVB Leerink analyst Geoffrey Porges wrote in… Read More »

Drug-therapy combo cuts breast cancer recurrence risk by 25%, Eli Lilly announces

Eli Lilly and Company on Sunday announced positive results in the fight against breast cancer. A drug called Verzenio, also known as abemaciclib, in combination with adjuvant endocrine therapy, was said to “significantly” reduce the risk of breast cancer recurrence by 25% for those with a common subtype of breast cancer. The combo treatment also lowered the risk… Read More »

FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer

FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer Print this page South San Francisco, CA — June 29, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo, a fixed-dose combination (FDC) of Perjeta® (pertuzumab)… Read More »